Real-World check: targeted drug MIRV tested against tough ovarian cancer
NCT ID NCT07687602
First seen Jul 07, 2026 · Last updated Jul 08, 2026 · Updated 1 time
Summary
This study monitors the safety and effectiveness of mirvetuximab soravtansine (MIRV) in people with a specific type of ovarian, fallopian tube, or primary peritoneal cancer that has stopped responding to platinum-based chemotherapy and tests positive for the folate receptor-alpha protein. About 69 participants in South Korea who have already tried one to three prior treatments will receive MIRV as part of their routine care and be followed for up to 62 months. The goal is to see how well the drug works and what side effects occur in everyday clinical practice.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- Active substance
- mirvetuximab soravtansine (MIRV)
- What this could lead to
- If successful, this could confirm that MIRV is a safe and effective treatment option for people with this hard-to-treat ovarian cancer in real-world settings.
- What could go wrong
- This is an observational post-marketing study, not a controlled trial, so results may be less definitive. Side effects are possible, and the small size (69 participants) limits general conclusions.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Participants
-
About 69 people
The number the study aims to enrol. It can still change while the study runs.
- Expected to start
-
Jun 2026
An estimate. Start dates often move.
- Expected to finish
-
Aug 2031
An estimate. End dates often move.
- Lead sponsor
-
A company
The lead sponsor is a pharmaceutical, biotech, or medical-device company.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
Who is studied
Adult participants who started treatment with MIRV according to the approved product label in South Korea.
- Ages
-
18 years and older
- Sex
-
Female participants only
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: \- Folate receptor-alpha (FRα) positive (\>=75% of cells with \>=2+ staining intensity) platinum-resistant, high-grade serous epithelial ovarian, fallopian tube, or primary peritoneal cancer, who have received one to three prior systemic treatment regimens, according to the approved product label Exclusion Criteria: * Participants who are contraindicated from approved label of mirvetuximab soravtansine-gynx (MIRV). * Participants who are currently participating in a clinical trial of another investigational drug.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Folate receptor-alpha positive platinum-resistant fallopian tube cancer are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
How to take part
Only the study team decides who joins. These are the ways to reach them.
-
The official record
ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.
-
A doctor treating you
A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.